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The use of long-acting glucocorticoids in the treatment of individuals with Congenital Adrenal Hyperplasia (CAH) has been
greeted with controversy. Avoidance of dexamethasone therapy is in part due to the mistaken assumptions that dexamethasone
is 30-fold more potent than hydrocortisone in suppressing adrenal activity, resulting in the overtreatment and the “growth
toxic” label. However, as shown more than 50 years ago, dexamethasone is 80- to 100-fold (or greater) more potent than
hydrocortisone in suppressing adrenal androgen production. When children are treated with low doses of dexamethasone once
dailyinthemorning(0.15–0.3mg/m2/dayofdexamethasoneversus10–25mg/m2/dayofhydrocortisone),studiesinvolvinginfants
and children show that normal growth and skeletal maturation can be achieved, along with appropriate suppression of adrenal
androgen secretion. Due to its high potency, the potential for overtreatment remains high with dexamethasone. Thus, it is
imperative that dexamethasone-treated children be closely monitored.
1.Introduction
The use of long-acting glucocorticoids in the treatment
of individuals with Congenital Adrenal Hyperplasia (CAH)
has been greeted with controversy [1]. A large part of
this controversy rests on the mistaken assumption that
prednisone is 5 times more potent than hydrocortisone
and dexamethasone is 30 times more potent than hydro-
cortisone in suppressing adrenal androgen production [2].
These literature entrenched equivalencies are based on anti-
inﬂammatory properties [2]. And when prednisone and
hydrocortisone are used at 5- and 30-fold potencies relative
to hydrocortisone, respectively, children will be overtreated
[3, 4].
As observed more than 50 years ago by Wilkins and
coworkers, prednisone and dexamethasone are 15- and 80-
fold more potent than hydrocortisone that in suppressing
adrenal androgen production, respectively [5]. These relative
dose equivalencies have been reaﬃrmed in clinical studies
[6–9], and when prednisone and hydrocortisone are used at
the higher potency equivalency ratios, children can be eﬀec-
tively treated with these long-acting glucocorticoids [6–8].
2. Origins of Dexamethasone Therapy of CAH
The use of dexamethasone in the treatment of CAH was
introduced in 1971 by Hayek et al. [10]. The authors noted
“Elucidation of the circadian rhythm of ACTH release, and
the demonstration that secretion as reﬂected by low 8 a.m.
cortisol levels can be eﬃciently suppressed by a single 1-
mg dose of dexamethasone, led us to investigate the eﬃcacy
of prolonged administration of the this compound once
daily as an alternative to the conventional three daily dose
in the treatment of patients with CAH”. In detailed acute
studies of four patients with CAH, daily administration of
dexamethasone resulted in normalization of 17-ketoseteroid
and pregnanetriol excretion (Figure 1). The dexamethasone
doses used in these studies were 0.2 to 0.5mg/m2.
3. Universityof Wales College of Medicine
Studiesof Dexamethasone
Inthe1980sHughesandcolleaguesattheUniversityofWales
College of Medicine (Cardiﬀ, UK) published an elegant2 International Journal of Pediatric Endocrinology
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Figure 1: Responses of patients with congenital adrenocortical hyperplasia syndrome to cortisone in three daily doses as contrasted with
those to single dose of dexamethasone at midnight. Black dots: values for daily excretion of urinary 17-ketosteroid; open circles: 24 hr
excretion of pregnanetriol. Amount of medication in each period is shown by height of bars below abscissal scale. Patients (a) and (b) had
“incomplete” form of 21-hydroxylase deﬁciency; (c) and (d) had “complete” salt-wasting variant. From [10].
series of publications relating to dexamethasone use in CAH
[9, 11–14].
When applied to girls with CAH, menarche or regular
menses occurred when plasma testosterone concentrations
became normal using a single daily dexamethasone dose of
0.25–0.75mg/day. As observed by Wilkins [5], it was noted
“The potency of this glucocorticoid in suppressing adrenal
steroid biosynthesis relative to cortisol is about 80:1. The
onset of regular, ovulatory menstrual cycles, as judged by
daily salivary progesterone proﬁles, was achieved within 2-
3 years of menarche using this treatment regimen. Such
patients have a good prognosis for normal fertility.” [12].
The use of dexamethasone was further detailed in
another group of patients with CAH, in which hormonal
control was monitored by frequent, serial measurements
of saliva 17OH-progesterone (17OHP) concentrations [13].
Data showed that, when used, dexamethasone therapy
resulted in adequate adrenal suppression [13].
Dexamethasone pharmacokinetics was studied in CAH
using a radioimmunoassay [14]. The authors observed that
dexamethasone remained in the circulation for about 16
hours after administration, with a half-life of about 4
hours. Thus the pharmacological eﬀects of dexamethasone
may extend beyond the time in circulation. Suppression of
the hypothalamo-pituitary-adrenal axis also correlated with
plasma dexamethasone levels [14]. There were consider-
able interindividual diﬀerences in dexamethasone clearance,
which was postulated to explain the diﬀering dose and
dose schedule requirements necessary to achieve adequate
therapeutic control in the clinical management of CAH [14].International Journal of Pediatric Endocrinology 3
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Figure 2: Response to dexamethasone therapy as related to time of day of treatment. Note that treatment in the evening increased the
likelihood of overtreatment. From [11].
Changesin17OHPconcentrationswerealsoreportedfor
13 patients with CAH given a single dose of dexamethasone
(0.01mg/kg) given in the morning [9]. Treatment resulted in
rapiddropin17OHPlevels,whichremainedlowthroughout
the day until the onset of an abrupt nocturnal rise between
24.00 and 05.00hr [9].
Results of short-term dexamethasone therapy in 10
patients with CAH (12–29 years) were later reported [11].
Three crossover dosage regimens were tested. A starting dose
of 5mcgper/kg (∼0.2mg/m2)w a su s e d[ 11]. Importantly
results indicated that when the same dose was given in the
evening,ascomparedtothemorning,patientswereobserved
to show clinical signs of overtreatment (Figure 2)[ 11]. These
observationsshowthatwhendexamethasoneisusedatnight,
as by some [15], there is a greater risk for overtreatment than
when the dose is given in the morning. At present, we do
not know whether the potential risk of overtreatment with
dexamethasone use in the evening can be mitigated with
using lower doses or whether this phenomenon reﬂects a
non-dose-related, time of day eﬀect.
4. Long-Term Treatment of
CAH with Dexamethasone
In the late 1970s and 1980s, Crawford and colleagues began
to routinely use dexamethasone in treating children with
CAH. In 2000, this experience was reported for 26 boys
and girls with CAH [7]. Thirteen boys and 8 girls were
diagnosed with 21-hydroxylase deﬁciency; 4 boys and 1 girl
were diagnosed with 11-hydroxylase deﬁciency.
Based on the bone ages (BAs) at the onset of dexametha-
sone therapy, patients were arbitrarily divided into 2 groups:
those children in whom the BA was within 2 years of the
chronological age (CA) at therapy onset (BA = CA; 13 males
and 6 females) and those children in whom the BA was 2
yearsgreaterthantheCAattherapyonset(BA CA;4males
and 3 females). Biochemical monitoring was performed
by assessment of urinary 17-ketosteroid and pregnanetriol
excretions, along with measurement of circulating 17OHP
levels.
A 0.1mg/mL elixir of generic dexamethasone was used.
Doses were administered between 7:00 and 9:00 a.m. using
a dosing syringe. When the patients were ill, parents were
instructed to give a double dose in the morning and the same
doubledoseintheeveningforthedurationofillnessplusone
day.
Patients were considered undertreated when 17-keto-
steroid secretion rates increased above the normal ranges for
age (1–8 years,0.5–2.0mg/day; 8–12 years, 2.5–8mg/day;
12–16 years, 8–22mg/day). Patients were considered
overtreated when the growth rate slowed, the face became
round, there was an increase in body hair, or the body4 International Journal of Pediatric Endocrinology
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Figure 3: (a) and (b) Changes in skeletal maturation during dexamethasone therapy. Bone ages (BAs) are depicted at the onset of
dexamethasone therapy and at the end of the observation period before epiphyseal fusion. The stippled diagonal line represents the line
of identity between BA and chronological age (CA). • indicates BA within 2 years of CA at therapy onset; o indicates BA > 2 years of CA
at therapy onset. (c) and (d) Changes in skeletal maturation relative to height during dexamethasone therapy. BAs and HAs are depicted at
the onset of dexamethasone therapy and at the end of the observation period or just before epiphyseal fusion. The stippled diagonal line
represents the line of identity between BAs and height ages (HAs). • indicates BA within 2 years of CA at therapy onset; o, BA > 2 years of
CA at therapy onset. From [7].
weight increased more than expected for changes in
height. In addition, if the morning 17-hydroxyprogesterone
values were within or lower than the normal range for age
(<200ng/dL) andtheACTHconcentrationwas<120pg/mL,
overtreatment was suspected.
Most patients were well controlled on single-morning
dose, ranging between 0.24 and 0.33mg/m2/day (0.27 ±
0.01mg/m2/day). Two patients required daily doses of
0.44 and 0.71mg/m2/day, divided among a morning dose
(2/3) and an evening dose (1/3). Five patients required
relatively lower doses of dexamethasone. Compared with
standard hydrocortisone doses, which can range from 10–
25mg/m2/day[1],wethusfounddexamethasonetobeabout
80–100 fold more potent than hydrocortisone.
During treatment with dexamethasone, growth was
observed for an average of 7 years. In the patients withInternational Journal of Pediatric Endocrinology 5
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Figure 4:Matureheights (solidsymbols)orpredicted adultheights
(open symbols) after treatment with dexamethasone. Heights are
given as SDS or percentile.  indicates females; ◦ indicates males.
From [7].
comparable skeletal and chronological ages at the onset of
therapy,theheightandskeletalmaturationincreasedpropor-
tionately during dexamethasone treatment (Figure 3). The
children without signiﬁcant BA advancement at the onset
of dexamethasone therapy, who had completed growth,
had ﬁnal heights that were similar to midparental heights
(Figures 4 and 5). For the boys and girls who were still
growing, predicted adult heights were similar to midparental
heights (Figures 4 and 5). Individuals with advanced bone
ages at therapy onset had mature and predicted adult heights
that were well below the 5th percentile and midparental
heights (Figures 4 and 5). Importantly height projections
increased while being on dexamethasone treatment.
During treatment with dexamethasone, 17-ketosteroid
excretion rates were 1.92 ± 0.21mg/24 hours from 0 to 4
years, 1.92 ± 0 . 2 1m g / 2 4h o u r sf r o m4t o8y e a r s ,3 . 4 2±
0.5mg/24 hours from 8 to 12 years, and 6.7 ± 0.76mg/24
h o u r sf r o m1 2t o1 6y e a r so fa g e .
Recognizing that few clinicians now rely on 24-hour
urine collections to assess adrenal control, we now measure
circulating levels of 17-hydroxyprogesterone, androstene-
dione, and testosterone late in the day to assess con-
trol of adrenal androgen production. Using this mon-
itoring approach, we now aim for late afternoon 17-
hdroxyprogesterone levels between 250 and 1,000ng/dL, and
androstenedione and testosterone levels up to 2-fold above
normal.
5. Treatment of CAH with Dexamethasone
Beginning inInfancy
Following studies of dexamethasone in older children, we
applieddexamethasonetothetreatmentofinfantswithCAH
[8]. Three boys and 5 girls were identiﬁed as having CAH
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Figure 5: Mature heights (solid symbols) or predicted adult
heights (open symbols) of children treated with dexamethasone,
compared with midparental heights corrected for sex. The stippled
diagonal line represents the line of identity between patients’ and
midparental heights. (a) depicts patients with BA within 2 years of
CA at therapy onset; (b) depicts patients with BA > 2 years of CA at
therapy onset.  indicates females; ◦ indicates males. From [7].
by newborn screening and treated with dexamethasone from
birth until about 7 years of age, when data were analyzed.
Dexamethasone was administered at an initial dose of
0.1mg each morning (0.1mg/mL elixir of generic dex-
amethasone). Doses were administered between 7:00 and
9:00 a.m. using a dosing syringe. Laboratory tests were
obtained between 3:00 and 5:00 p.m. for determination
of circulating concentrations of 17-hydroxyprogesterone,6 International Journal of Pediatric Endocrinology
0
0
1
1
2
2
3
3
4
4
5
5
B
A
CA
Figure 6: Bone age (BA) versus chronological age (CA) in children
treated with dexamethasone for CAH from birth. Dashed line is the
line of unity. From [8].
androstenedione, testosterone, renin, and electrolytes. Doses
were increased when the 17-hdroxyprogesterone levels were
above 1,000ng/dL and the androstenedione and testosterone
levels were more than 2-fold above normal. Doses were
decreased when the 17-hydroxyprogesterone levels were less
than 250ng/dL and the androstenedione and testosterone
levels were normal or below normal, or there was excessive
weight gain assessed at home (>0.5kg in 2 weeks). When
dose adjustments were made, doses were generally changed
by 10%. Laboratory testing was repeated 2 months after dose
changes.
The average dose initially used for treating the infants
with dexamethasone was 0.25mg/m2/day. As the infants
became older, most remained on a dexamethasone dose
within 30% of the absolute dose started in infancy. At
the end of the followup period, the average daily dose of
dexamethasone was 0.18mg/m2/day. Thus, as in the older
children, dexamethasone was estimated to be 80–100 fold
more potent than hydrocortisone.
When the linear growth was evaluated, growth rate Z
scores were 1.1 ± 0.1. At an average of 6.5 years of age
height Z scores were 0.5 ± 0.2 and the average body mass
index (BMI) was 18.2 ± 1.5. The mean bone age was 5.1
± 1.5 years, with a bone age to chronologic age ratio of 0.9
± 0.6 years (Figure 6). Thus, based on growth and skeletal
maturationparameters,thelineargrowthindexamethasone-
treated children appears normal. Long-term followup of
these children though will be needed to ascertain long-term
outcomes more than one decade from now.
When circulating androgen levels were assessed, they
were measured at the end of the day. Testing was performed
atthistimeasovertheyearsweassessedcirculatinghormone
levels at diﬀerent times of the day, and we found that late
afternoon levels correlated best with dose adjustments that
allowed us to optimize growth and normal weight gain. At
late afternoon, circulating testosterone and androstenedione
levels were close to, or 2-fold above, the normal range. The
17-hydroxyprogesterone levels were 10- to 20-fold above
normal.
6. TreatmentofChildrenwithNonclassicalCAH
withDexamethasone
In addition to treating children with classical CAH, we have
treated a cohort of 8 boys with nonclassical forms of CAH
who presented with bone ages that were more than 4 years
advanced relative to chronological ages. All children had 21-
hydoxylase deﬁciency.
Dexamethasone was administered as an initial dose of
0.2mg/m2 per day each morning. A 0.1mg/mL elixir of
generic dexamethasone was used. Testing and dose adjust-
mentweremadeasdetailedabove.Attheendofthefollowup
period of 5 years, the average daily dose of dexamethasone
was 0.15mg/m2/day.
When the linear growth was evaluated, growth rate
Z scores were 1.0 ± 0.1. The change in bone age to
chronological age was 0.67 ± 0.05 years. Later afternoon
17OHP levels were 682 ± 157 ng/dL, testosterone 125 ±
37ng/dL, and androstenedione 58 ± 10ng/dL.
7. Summary
Following the discovery of hydrocortisone as a treatment
of CAH by Fuller Albright and colleagues at Massachusetts
General Hospital [16] and Lawson Wilkins and coworkers at
Johns Hopkins University [17], thousands of lives have been
saved and children born with CAH now have a bright future.
Although we know a lot about the condition, CAH remains
a complicated condition to treat, warranting close vigilance
[1]. Recognizing the inherent limitations and inconvenience
of using short-acting compounds, there is a natural desire
for longer-acting drugs to allow once-a-day dosing and
avoid the wide swings in circulating adrenal androgen levels
associated with hydrocortisone therapy. Dexamethasone ﬁlls
this need as a long-acting preparation, which can be used
for pennies a day. As such, eﬀorts to develop a long-
acting hydrocortisone preparation [18], which will come at
dramatically higher price point than dexamethasone, can be
viewed as superﬂuous.
Dexamethasone use is not for the casual practitioner.
Due to its high potency, the potential for overtreatment
remains high. Dilute preparations (0.1mg/mL), rather than
small pills that are cut, or more concentrated preparations,
arerecommended.Dosingsyringesareessentialforthedeliv-
ery of the prescribed dose; medicine-droppers, teaspoons,
andmedicationcupshavenoroleindexamethasonetherapy.
Although it is tempting to give the dose at night to suppress
morning adrenal androgen production, nighttime dosing of
dexamethasone is associated with overtreatment [11]. Thus,
the morning is the favored time for administration. Most
importantly,irrespectiveoftheinitialdoseofdexamethasone
(or hydrocortisone) used, it is essential that treatment be
tailored to the individual child based on patterns of growth,
maturation, and circulating androgen levels.
In applying dexamethasone therapy to children with
CAH, the past and more recent lessons of steroid potency
must be engaged [4]. The mistaken assumptions that
prednisone is 5 times more potent than hydrocortisone andInternational Journal of Pediatric Endocrinology 7
dexamethasone is 30 times more potent than hydrocortisone
in suppressing adrenal androgen production need to be
abandoned,asprednisoneanddexamethasoneare10–15and
80–100fold(orgreater)morepotentthanhydrocortisone,in
suppressing adrenal androgen production, respectively [4].
In failing to do so, children will be overtreated, perpetuating
the myth of the “growth toxic” glucocorticoid.
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